CeriBell (NASDAQ:CBLL – Get Free Report)’s share price reached a new 52-week low on Monday . The stock traded as low as $20.06 and last traded at $20.13, with a volume of 13957 shares. The stock had previously closed at $20.93.
Analyst Upgrades and Downgrades
Several brokerages have commented on CBLL. Canaccord Genuity Group began coverage on shares of CeriBell in a research note on Tuesday, November 5th. They issued a “buy” rating and a $30.00 target price for the company. TD Cowen raised their price objective on CeriBell from $31.00 to $36.00 and gave the stock a “buy” rating in a research note on Monday, December 9th. Canaccord Genuity Group boosted their target price on CeriBell from $31.00 to $33.00 and gave the company a “buy” rating in a research note on Monday, December 9th. William Blair started coverage on CeriBell in a research report on Tuesday, November 5th. They set an “outperform” rating on the stock. Finally, Bank of America started coverage on CeriBell in a research report on Tuesday, November 5th. They issued a “buy” rating and a $32.00 price objective for the company. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $32.60.
Read Our Latest Research Report on CBLL
CeriBell Price Performance
CeriBell (NASDAQ:CBLL – Get Free Report) last released its earnings results on Tuesday, November 12th. The company reported ($1.85) EPS for the quarter, missing the consensus estimate of ($0.82) by ($1.03). The business had revenue of $17.20 million during the quarter, compared to analysts’ expectations of $17.06 million. As a group, equities research analysts anticipate that CeriBell will post -2.46 earnings per share for the current year.
About CeriBell
We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.
Featured Articles
- Five stocks we like better than CeriBell
- Are Penny Stocks a Good Fit for Your Portfolio?
- The Fed Is More Likely to Hike Than Cut Rates in 2025
- Market Cap Calculator: How to Calculate Market Cap
- Investors Navigate Uncertainty by Seeking Refuge in Gold and Oil
- How to Use the MarketBeat Excel Dividend Calculator
- Archer Aviation Shares Slide, Now Bargain Priced for 2025
Receive News & Ratings for CeriBell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CeriBell and related companies with MarketBeat.com's FREE daily email newsletter.
